Receptor tyrosine kinase inhibitors in thyroid cancer
Best Practice & Research Clinical Endocrinology & Metabolism, ISSN: 1521-690X, Vol: 22, Issue: 6, Page: 1023-1038
2008
- 35Citations
- 62Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations35
- Citation Indexes35
- 35
- CrossRef30
- Captures62
- Readers62
- 62
Review Description
Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1521690X08001097; http://dx.doi.org/10.1016/j.beem.2008.09.012; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=56849101569&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19041829; https://linkinghub.elsevier.com/retrieve/pii/S1521690X08001097; https://dx.doi.org/10.1016/j.beem.2008.09.012
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know